Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;29(5):e70244.
doi: 10.1111/jcmm.70244.

SERS-Based Assessment of DNA Methylation for the Evaluation of Measurable Residual Disease in Acute Promyelocytic Leukaemia

Affiliations

SERS-Based Assessment of DNA Methylation for the Evaluation of Measurable Residual Disease in Acute Promyelocytic Leukaemia

Anamaria Bancos et al. J Cell Mol Med. 2025 Mar.

Abstract

Acute promyelocytic leukaemia (APL) is a type of acute myeloid leukaemia characterised by the reciprocal translocation t(15;17), which offers a unique possibility for measurable residual disease (MRD) monitoring by PCR amplification of the PML-RARA transcripts. Surface-enhanced Raman scattering (SERS) is a laser molecular spectroscopy technique that allows the rapid analysis of changes in the DNA methylation pattern associated with malignant transformation. In this study involving 49 DNA samples from bone marrow aspirations from patients with APL, we showed that the DNA from MRD-positive samples exhibited lower SERS intensities of the band at 730 cm-1 attributed to adenine. Next, we used the scores derived from principal component analysis (PCA) as input data for machine learning algorithms trained to categorise SERS spectra based on MRD status. The results showed that the highest classification accuracy was achieved by logistic regression, yielding an area under the ROC curve (AUROC) of 0.90. In addition, PCA showed that samples corresponding to patients with FLT3-ITD mutations had a tendency for unsupervised clustering irrespective of MRD status. These results suggest that SERS analysis of DNA represents a promising method for the MRD monitoring of APL patients. Future validation of these findings in large prospective studies is warranted.

Keywords: SERS; acute promyelocytic leukaemia; minimal residual disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
(A) Mean spectra of processed SERS spectra of genomic DNA samples from 15 acute promyelocytic leukaemia patients measurable residual disease (MRD) positive for PML‐RARA and 34 samples MRD negative for PML‐RARA; (B) Score plot depicting principal component 1 (PC1) and PC2 of SERS spectra from DNA; (C) Score values for PCs that exhibited statistically significant values between the MRD positive and MRD negative groups by Student`s t test (*p < 0.05; ***p < 0.001); (D) The loading plots for PCs that exhibited statistically significant values between the MRD positive and MRD negative groups; (E) The receiver operating characteristic curves for the discrimination between the MRD positive and MRD negative groups.

References

    1. Yilmaz M., Kantarjian H., and Ravandi F., “Acute Promyelocytic Leukemia Current Treatment Algorithms,” Blood Cancer Journal 11, no. 6 (2021): 123. - PMC - PubMed
    1. Ten Cate H. and Leader A., “Management of Disseminated Intravascular Coagulation in Acute Leukemias,” Hämostaseologie 41, no. 2 (2021): 120–126. - PubMed
    1. Burnett A. K., Russell N. H., Hills R. K., et al., “Arsenic Trioxide and All‐Trans Retinoic Acid Treatment for Acute Promyelocytic Leukaemia in all Risk Groups (AML17): Results of a Randomised, Controlled, Phase 3 Trial,” Lancet Oncology 16, no. 13 (2015): 1295–1305. - PubMed
    1. Ramos Perez J. M., Patel K. P., Loghavi S., et al., “Value of Measurable Residual Disease Monitoring in Patients With Acute Promyelocytic Leukemia in the Era of Frontline ‘Chemotherapy‐Free’ Therapy,” Leukemia & Lymphoma 63, no. 3 (2022): 672–675. - PMC - PubMed
    1. Schnittger S., Bacher U., Haferlach C., Kern W., Alpermann T., and Haferlach T., “Clinical Impact of FLT3 Mutation Load in Acute Promyelocytic Leukemia With t(15;17)/PML‐RARA,” Haematologica 96, no. 12 (2011): 1799–1807. - PMC - PubMed

Substances

LinkOut - more resources